Nanostructured HPMC Gel Embedding Niclosamide‑Leciplex: A Biomaterials Approach to Cellulitis Treatment

Skin infections are a common and often stubborn problem for doctors and patients alike. When the skin's protective barrier is broken by a cut or an insect bite, bacteria can slip inside, causing a painful, red, and swollen condition known as cellulitis. While antibiotics are the standard treatment, the overuse of these drugs has led to a growing crisis: many bacteria, including a dangerous strain called MRSA, have learned to resist them. This leaves patients with fewer options and doctors facing a difficult challenge. In the search for new solutions, scientists have looked at older drugs that might work in unexpected ways. One such drug is niclosamide, originally designed to treat worm infections in humans. Recent research has shown it can also kill certain bacteria by disrupting their internal energy supply, but the drug has a major flaw: it does not dissolve well in water and is very poorly absorbed when taken by mouth, making it difficult to deliver effectively to an infection site.

To solve this delivery problem, a team of researchers has developed a new way to apply niclosamide directly to the skin using a specialized gel. Their approach involves trapping the drug inside tiny, microscopic bubbles called lecithin-based nanoparticles, which act like a vehicle to carry the medicine deep into the skin layers where the infection lives. These bubbles are then embedded into a thick, soothing gel made from a plant-based polymer. This combination allows the drug to stay on the skin longer, penetrate deeper than it could on its own, and release slowly over time. The researchers tested this new formulation on mice with skin infections caused by the same bacteria that cause human cellulitis, and the results suggest this method could offer a powerful new tool for treating stubborn skin infections without relying on traditional antibiotics.

The journey to create this treatment began with the challenge of getting the drug into the skin. Niclosamide is naturally resistant to water, which means it struggles to mix with the fluids in our bodies or penetrate the tough outer layer of the skin. The researchers first turned to a nanotechnology approach, creating the tiny bubbles, or lecithin-based nanoparticles, to act as a carrier. They mixed the drug with natural fats and a specific type of salt to form these microscopic structures. By carefully adjusting the amounts of each ingredient, they were able to create bubbles that were small enough to slip through skin barriers and strong enough to hold the drug securely inside. The team found that the best version of these bubbles was nearly 120 nanometers in size, a scale so small that millions could fit on the head of a pin, and they held onto the drug with an efficiency of nearly 99 percent. This high efficiency meant that almost none of the valuable medicine was wasted during the creation process.

Once the drug was safely inside the bubbles, the researchers faced a second challenge: keeping the bubbles in place on the skin. If applied as a simple liquid, the bubbles would run off or evaporate too quickly to do their job. To fix this, they mixed the drug-filled bubbles into a gel made from hydroxypropyl methylcellulose, a substance derived from plant fibers that is commonly used in food and medicine to thicken liquids. This gel was designed to be smooth, easy to spread, and safe for the skin, with a pH level that matched the natural acidity of human skin to avoid irritation. The resulting mixture was a thick, yellow gel that could be applied directly to a wound. The researchers tested how this gel behaved and found that it flowed easily when spread but held its shape well, ensuring it would stay on the infected area long enough to work.

The true test of this new treatment came when the researchers examined how well it moved through the skin and killed bacteria. In laboratory tests using skin samples, the gel proved to be far superior to the drug applied in a simple liquid form. While the liquid version barely penetrated the skin, the gel allowed the drug to travel deep into the lower layers where the infection resides. The drug was found to be seven times more effective at moving through the skin when delivered in this gel format. Furthermore, the gel released the drug slowly over a full day, providing a steady stream of medicine to the infection site rather than a quick burst that would disappear rapidly. When tested against the bacteria that cause cellulitis, including the drug-resistant MRSA strain, the gel showed a remarkable ability to stop bacterial growth. It was effective at concentrations as low as 0.96 micrograms per milliliter, a level significantly lower than what was needed for the drug in its liquid form.

To see if these laboratory results would translate to real healing, the team applied the gel to mice with skin infections that mimicked human cellulitis. The results were striking. Mice treated with the new gel saw their wounds shrink dramatically, with the infected area reducing to less than one square centimeter within ten days. In contrast, mice treated with the drug in a simple liquid form saw their wounds remain large or even grow, and untreated mice suffered from severe, expanding infections. The researchers also examined the skin tissue under a microscope and found that the gel-treated mice had skin that was healing normally, with reduced swelling and inflammation, while the other groups showed signs of ongoing damage and infection. The study concludes that this new gel formulation successfully overcomes the limitations of the drug, offering a safe, effective, and patient-friendly way to treat cellulitis by delivering the medicine exactly where it is needed most.